Member Info for Mikey279

Do our competitors have a CE marked potentially leading product in the early stages of an unprecedented global crisis?

Nope.... jog on buddy, probably still be spouting the same **** further donw the line like our good friends marie and durian

Anyway a 7 EUR analyst target, nice.

No point comparing against a pharma in a supressed economy.... nor mentioning an article dated the 4th prior to any announcement of NHS usage, FDA application and intention to release a CE product

"Outside of China, the incidences of Coronavirus are still well below the annual figures for influenza which continues to be a bigger killer."

Clearly haven't done any research into the virus and stage of cycle it's currently at.... I also find that those who mention flu as a bigger killer the most ill-informed. Take a look at the infection rate and number of people serious/critical condition (the numbers not reported by the media), then consider unknown components such as re-infection, mutation, different dosage's of the virus..... but it's okay flu kills more people so it's a nothing situation right?

Jealousy is unattractive.

For balance, if you want to talk about real risk in terms of SP: FDA rejection, a superior CE marked product with 100% accuracy and faster diagnosis times, a vaccination

DYOR

Meeting demand isn’t going to be an issue, receiving demand is the key - every pharma in the world will want a roll out agreement if we have the leading product

It’s an unprecedented situation and a black swan event so pretty much unlimited upside due to the 60m shares and global coverage

All IMO though.... there’s obviously competition risk etc but the virus isn’t going away any time soon

I've been doing some heavy research on the virus itself..... I don't think people understand the scale of the virus and the demand requirements for tests..... when reports eventually and undoubtedly come out that not all infected originated from china, people with generic flu symptoms will be tested for the virus globally. And only then you will realise the potential of and importance of companies like Novacyt.....lets see if £5-£10 is still pie in the sky if our product becomes market leader.

https://www.cnbc.com/2020/02/14/us-health-officials-to-check-patients-with-flu-symptoms-for-coronavirus.html

https://asia.nikkei.com/Spotlight/Coronavirus/None-of-Japan-s-new-coronavirus-patients-had-direct-China-links

£5.... in a few weeks lets see

Have a good weekend

A lot of people dont use twitter nor LSE.... so rns is good

Spoke too soon.... officially released

Early early days yet... test unofficially released via twitter, so in terms of official info - nothing has changed

Target £5.... only 60m shares in issue

we had 2m at 31st December.... plus any order will likely be cash up front from multiple buyers, should be ok

just looking at cash levels, they have around £2m after warrant money excluding money from RUO tests - so should be OK?

How many tests are needed... per person, for stock piling, imagine we do become the lead supplier globally... £1b company +?

100m tests at £5 per test

The speed of movement is impressive, they targeted w/c 17th, so could have been up until end of next week, but managed a release in the space of 4 days..... you can imagine they're moving fast for good reason, now for ROLLOUT

I was initially dubious of the rise as it was an RUO product, but they managed a CE diagnostic in the space of 2 weeks.... confident this will reach £5 levels, if the interest of product is high enough to be the dominant supplier

All IMO though DYOR

Where's my guy durian fruit.... '25p'

£5 target depending on roll out now.....

DYOR

As per yesterday, if it crosses £7 trading the wife for a younger model

Holy crap didn't expect the product until well into next week.... they're moving fast

RNS inbound... £5 inbound!!

GL ALL DYOR

Shut up durian, you missed out at 40p, talking **** at 80p and will probably still do the same in the £s..... jealousy isn’t attractive

how can they list over there with no rns lol......boom i guess

There won't be a buy out, not in the near future anyway.... too much DD required when primary goal would be to roll out and set up distribution networks for the tests.... if it were to happen you'd usually get x number of shares in buying company and/or cash.

Highly likely to be a JV of some sort if the tests do prove to be market leading.... although we do generate millions in revenue already so may be not required

consider the speed they need to move at... ASAP